Abstract
The accidental discovery of smallpox vials at the National Institutes of Health earlier this year quickly attracted the attention of the health and security communities. Smallpox was officially eradicated decades ago, and is only supposed to exist in two carefully guarded labs – and the National Institutes of Health isn’t one of them! This interview focuses on a biotech company that has spent the last 10 years developing a vaccine against what has so far been a non-existent disease. It discusses possible avenues for the re-emergence of smallpox, including the impact of developments in synthetic biology, and it gives an inside view on the biodefence industry and its unusual business model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
